Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is highly overexpressed in primary and metastatic prostate cancer (PCa).
diagnostic or therapeutic purpose in the clinicaltrials.gov database.
PSMA protein is expressed in the kidney, gut, brain, peripheral nerves, salivary glands, and prostate of humans. In malignant tissues, expression can be detected in the neovasculature of multiple cancer types, and is highly upregulated in prostate cancer tissues.
Expression in prostate cancer increases with disease stage of and the majority of both soft-tissue and osseous metastases highly express the antigen. Mice are commonly utilized to more deeply understand the etiological basis and impact of protein expression, as well as to evaluate imaging agents and experimental agents in models of disease, and should be a useful tool to investigate PSMA function. Human and mouse PSMA share 86% sequence identity, with identical enzymatic activity. 3 However, PSMA expression patterns in mice are different than those found in man. Some reports have indicated low 3 or a lack 4 of expression of mouse FOLH1 (Folh1) in the mouse prostate, while others report moderate to high expression in normal prostate and in the TRAMP genetically engineered mouse model (GEMM) of prostate cancer. [5] [6] [7] Investigation of mPSMA in cancer progression and development have used transgenic mPSMA expressing tumor models 8 and PSMA knockout mice crossed with TRAMP mice 7, 9, 10 to suggest that PSMA promotes prostate cancer formation and progression.
Some of this discrepancy may be due to multiple similar family members that can interfere with specific detection of PSMA. Here we use multiple PSMA specific detection methods, including highsensitivity non-invasive in vivo positron emission tomographic (PET) imaging, to show little or no PSMA expression in normal mouse prostate, but highly upregulated expression in the Hi-Myc model of prostate cancer. This unexpected finding has significant import to improve our understanding of PSMA in disease biology and provides a validated research model for drug evaluation.
| RESULTS
In order to confirm the ability of antibodies used for immunohistochemistry to specifically detect PSMA expression in mouse tissues, we performed protein detection on tissues known to express PSMA. In kidney, PSMA expression was detected in proximal renal tubules and in
Bowman's capsule with the expected membranous staining pattern;
representative low (top) and high (bottom) magnification micrographs shown ( Figure 1A ). Specificity was confirmed by repeating the staining conditions in PSMA (Folh1) knockout mice ( Figure 1B ). PSMA expression was undetectable in all examined tissues from knockout mice, suggesting no apparent cross reactivity with other PSMA family members. Little to no expression was detected in normal prostate ( Figure 1D ) from wild-type mice.
In human prostate cancer samples ( Figure 1C ), high levels of PSMA expression was detected using the same antibody and revealed the expected pattern of membranous staining with concentration at the luminal border of epithelial cells. Surprisingly, in Hi-Myc mice ( Figures 1E and 1F ), PSMA expression was detected in PIN lesions ( Figure 1E ) and in invasive adenocarcinoma ( Figure 1F ) with a membranous expression pattern similar to human cancer. Tissue lysates prepared from wild type and Hi-Myc mice were similarly assayed for PSMA expression using the same antibody used for immunohistochemistry ( Figure 1G To confirm these in vivo results, the genitourinary package was promptly removed in its entirety, microdissected at 4°C and arrayed ( Figure 4A ). The tissues were rescanned and uptake, corrected for decay and injection activity, was analyzed ( Figures 4B and 4C Knockout animals, which have intact GcpIII (Folh2), did not stain positive and served to underline the specificity of our approach. In contrast with some previous reports, we detected minimal to no expression of PSMA in normal and TRAMP prostates. We relied on detection of PSMA protein using a monoclonal antibody and a small molecule, while some reports have detected Folh1 RNA. The reason for this discrepancy is unclear, but differing sensitivity of these methods or detection of highly similar homologs may explain these differences.
There are many agents under development for improved detection and targeted therapy of prostate adenocarcinoma. [15] [16] [17] [18] [19] The widespread use of high-sensitivity and robust methods to detect PSMA in particular in the locally advanced and metastatic settings by PET and SPECT are poised to revolutionize management for those afflicted with the disease. Further, many of these agents can be derivatized to deliver radioisotopes with therapeutic intent. [20] [21] [22] This creates the urgent need to better understand the underlying biology of the target protein, its expression in disease states and its response to novel and conventional therapies. We pursued in vivo imaging in order to evaluate whether the expression levels There is no definitive explanation for the absence of GCPII expression in normal mouse prostate, in contrast to that in man. One partial explanation for this is that models of prostatic disease are limited by several factors, key among these is that rodents, used for the bulk of biological evaluation in mammalian systems, do not naturally develop prostate cancer. Another is that within mice, PSMA expression patterns vary from sites in man. Some organs, including the gut, kidney and brain share common GCPII profiles across species. For example, while it has become evident that GCPII is often expressed in the neovasculature of several types of cancer in man, the presence of the protein is absent in xenograft models of cancer in mice. 24 Our finding of PSMA expression in the pre-and cancerous prostate of a well regarded mouse model is significant as it may be useful in elucidating the reason for the differences in expression in human and mouse tissues. Moreover, the use of PSMA-targeting agents is now being firmly established in clinical practice for diagnostic and therapeutic intent. We have previously found mouse models of considerable value in order to study the pharmacokinetic and radiobiological profile of established imaging agents and emerging radiotherapies. 30, 31 This work shows that the ability to direct molecularly specific ligands to diseased tissues may recapitulate clinical absorbed dose profiles at the tumor and off-target tissues is of considerable value to assess and optimize methods.
To conclude, our work extends the biological utility of this genetically engineered model system for use towards understanding the role of this abundant prostate cancer cell-surface marker in disease progression, and in drug development applications for anti-PSMA imaging and therapy evaluation. OH). 25 Briefly, this GEMM has excised exons 3-5 of GcpII/Folh1 and backcrossed in C57Bl/6>10 generations to generate homozygous PSMA-null mice. PSMA is undetectable in the knockout by PCR or
Western blot, and knockout mice express no basal phenotypic differences. 26, 27 Probasin-Cre x PTEN fl/fl mice were generated as previously described. 28 Genotyping was performed using primer sets and protocols recommended by the vendor. Genomic DNA for PCR was isolated from tails.
| Immunohistochemistry
Slides prepared from formalin fixed tissues were deparaffinized and rehydrated before steaming in EDTA pH 8 (Invitrogen) for 40 min.
Endogenous peroxidases were quenched with BLOXALL (Vector Labs), and the slides were blocked for 1 h with Serum Free Protein Block (Dako). Slides were incubated with antibodies directed against PSMA (Cell Signaling Technology rabbit monoclonal antibody (D7I8E).
Staining was visualized with ImmPRESS Polymer detection kit and
ImmPACT DAB (Vector Labs).
| Western blot
Lysates were prepared from flash frozen tissue samples using RIPA 
